Research programme: histamine H3 receptor antagonists - Merck & Co

Drug Profile

Research programme: histamine H3 receptor antagonists - Merck & Co

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Piperidines; Small molecules; Thiadiazoles; Urea compounds
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Allergic rhinitis; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for research development in Obesity in USA (PO)
  • 23 Aug 2012 Preclinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top